Contraindications of Librium (Chlordiazepoxide)
Librium is absolutely contraindicated in patients with glaucoma, prostatic hypertrophy with benign bladder neck obstruction, and known hypersensitivity to chlordiazepoxide or clidinium bromide (when used as Librax combination). 1
Absolute Contraindications
Based on FDA labeling, the following are formal contraindications:
- Glaucoma: The anticholinergic component (in Librax formulation) may produce mydriasis, worsening intraocular pressure 1
- Prostatic hypertrophy with benign bladder neck obstruction: Risk of urinary retention 1
- Known hypersensitivity: To chlordiazepoxide hydrochloride and/or clidinium bromide 1
Strong Clinical Contraindications (Not FDA-Listed but Critical)
While not explicitly listed in the FDA label, the following represent important clinical contraindications based on benzodiazepine class effects:
Concomitant MAO Inhibitor Use
- Absolute contraindication when used with monoamine oxidase inhibitors
- Risk of severe hypertension and cerebrovascular accident 2
Active Psychosis
- Benzodiazepines are psychotomimetic in patients with schizophrenia
- Should not be used in schizophrenia, psychosis NOS, or manic episodes with psychosis 2
Respiratory Disorders
- Contraindicated in patients with significant respiratory compromise 3
- Recent evidence shows 71% of ICU admissions after chlordiazepoxide required mechanical ventilation, with respiratory insufficiency being the most common presentation (39%) 4
- The "Too sedated" group had 21% mortality at 90 days 4
Coma
- Contraindicated in comatose patients 3
Special Population Warnings (Relative Contraindications)
Hepatic Insufficiency - Critical Consideration
Chlordiazepoxide should be avoided or used with extreme caution in hepatic insufficiency, despite being commonly prescribed for alcohol withdrawal in this population. Here's why:
- Chlordiazepoxide itself has minimal sedative activity—its effect depends primarily on hepatic metabolism to active metabolites 5
- In hepatic insufficiency, metabolism is markedly delayed, leading to "dose-stacking" where unmetabolized drug accumulates 5
- The metabolite demoxepam has a half-life of 14-95 hours (vs. 6.6-28 hours for parent drug), which is further prolonged in liver disease 5, 6
- This creates a delayed, profound, and prolonged sedative effect that is difficult to predict 5
- Poor correlation exists between cumulative doses, plasma concentrations, and clinical effects 7
- 85% of ICU-admitted patients had plasma concentrations above 3.5 mg/L, yet clinical outcomes varied unpredictably 7
Elderly Patients (Age >60-70 years)
- Initial doses should be 50% of standard adult doses 8
- Clearance is reduced and elimination half-life is prolonged 6
- Increased risk of ICU admission from chlordiazepoxide toxicity 9
- Higher risk of drowsiness, ataxia, confusion, and falls 1
Pregnancy
- Physical dependence is expected with regular use
- Abrupt discontinuation can cause life-threatening withdrawal 10
- Crosses placental barrier; may cause neonatal withdrawal 3
Common Pitfalls to Avoid
Intramuscular administration: Painful and results in slow, erratic absorption—should not be given IM 8
Abrupt discontinuation: Never stop chlordiazepoxide abruptly in physically dependent patients—risk of seizures, hallucinations, and life-threatening withdrawal 3, 10
Assuming therapeutic drug monitoring is helpful: Poor correlation between dose, plasma levels, and clinical effects makes TDM unreliable for guiding treatment 7
Overlooking drug interactions: Disulfiram therapy reduces clearance and prolongs half-life 6
Ignoring cumulative dosing risks: Patients receiving ≥200 mg cumulative doses are at significantly increased risk of ICU admission requiring mechanical ventilation 4, 9
Monitoring Requirements
When chlordiazepoxide must be used despite relative contraindications:
- Protracted therapy: Periodic blood counts and liver function tests are advisable due to rare reports of blood dyscrasias, agranulocytosis, jaundice, and hepatic dysfunction 1
- Elderly and hepatically impaired: More frequent assessment for sedation, respiratory depression
- Cumulative doses >200 mg: Consider higher level of monitoring given 0.35% overall incidence of severe toxicity requiring ICU admission 9